BEACON – New York Blood Center will be holding a blood drive at Beacon High School on Wednesday, November 9 from 730 a.m. to 600 p.m. in honor of Paris Moore. The public is encouraged to attend this drive after 230 p.m. if they are able. Paris graduated from Beacon High School in 2018. He was born with […]

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

2884041 views on Imgur The magic of the Internet

A former supervisory correctional officer ordered detainee abuse as well as allowed a white supremacist assault of two Black pretrial inmates.

Budget 2023 The health sector has been allocated Rs 89,155 crore in the Union Budget 2023-24, a hike of around 13 per cent over Rs 79,145 crore allocated in 2022-23, with the government also announcing a mission to eliminate sickle cell anaemia by 2047.

Demand for blood donations to treat the disease has risen by 67 per cent over the past five years

MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological […]

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

(marketscreener.com) Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT Company to provide a clinical update on the Phase 1/2...https//www.marketscreener.com/quote/stock/EDITAS-MEDICINE-INC-26123639/news/Editas-Medicine-Announces-Third-Quarter-2022-Results-and-Business-Updates-42175871/?utm_medium=RSS&utm_content=20221102

This is a ferrofluid display cell Bluetooth speaker that moves in response to music.

Demand is at record levels for blood to help people with the disease that mostly affects black people.

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

Companies investigate how therapies including Crispr might treat a debilitating genetic disease

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https//www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320

Two people with beta thalassaemia and one with sickle cell disease no longer need blood transfusions after their blood stem cells were gene edited and put back in their bodies

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

(marketscreener.com) Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient communityhttps//www.marketscreener.com/quote/stock/PFIZER-INC-23365019/news/Pfizer-Completes-Acquisition-of-Global-Blood-Therapeutics-41933646/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for BEAM-301 by Late 2023/Early 2024 and BEAM-302 in Early 2024 North...https//www.marketscreener.com/quote/stock/BEAM-THERAPEUTICS-INC-102685993/news/Beam-Therapeutics-Reports-Progress-Across-Base-Editing-Portfolio-and-Outlines-Key-Anticipated-Milest-42691060/?utm_medium=RSS&utm_content=20230109

(marketscreener.com) SITC 2022 Abstract 645 Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer ...https//www.marketscreener.com/quote/stock/VACCINEX-INC-45256990/news/Vaccinex-Phase-I-Study-of-Adoptive-T-Cell-Therapy-Following-HER2-Pulsed-Dendritic-Cell-Vaccine-and-42271853/?utm_medium=RSS&utm_content=20221110

Athersys is trying to succeed where many other biotechs have failed The stem cell therapy industry. Here's why they think they can.

(marketscreener.com) By Cecilia Butini Sanofi SA said Thursday that the European Union gave marketing authorization to a drug it developed to treat hemolytic anemia in adult patients with cold agglutinin disease, an autommune disease targeting red blood cells. The French pharma company said that its drug, a monoclonal antibody named Enjaymo, is currently...https//www.marketscreener.com/quote/stock/SANOFI-4698/news/Sanofi-Gets-EU-Nod-on-Hemolytic-Anemia-Drug-42347186/?utm_medium=RSS&utm_content=20221117

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https//www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https//www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320

Cellframe (CELL) Price Up 1.6% This Week

(marketscreener.com) ― Selected 12mg as the dose for next cohort in the Phase 1b trial of FTX-6058 in sickle cell disease ― ― Presented 96-week data from the Phase 2 ReDUX4 trial open label extension study at World Muscle Society conference ― ― Completed equity raise of approximately $80.8 million in net proceeds; Updated cash...https//www.marketscreener.com/quote/stock/FULCRUM-THERAPEUTICS-INC-62037838/news/Fulcrum-Therapeutics-Announces-Recent-Business-Highlights-and-Third-Quarter-2022-Financial-Results-42240611/?utm_medium=RSS&utm_content=20221108

(marketscreener.com) 2021 Annual Report Fueledby Connections A leader in the field of cellular metabolism pioneering therapies for genetically defined diseases Dianaba, Sickle Cell Disease Ryan,...https//www.marketscreener.com/quote/stock/AGIOS-PHARMACEUTICALS-IN-13709228/news/Agios-Pharmaceuticals-View-the-2021-Annual-Report-42514875/?utm_medium=RSS&utm_content=20221209

(marketscreener.com) BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for BEAM-301 by Late 2023/Early 2024 and BEAM-302 in Early 2024 ...https//www.marketscreener.com/quote/stock/BEAM-THERAPEUTICS-INC-102685993/news/Beam-Therapeutics-Reports-Progress-Across-Base-Editing-Portfolio-and-Outlines-Key-Anticipated-Milest-42691061/?utm_medium=RSS&utm_content=20230109

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological […]

Michael Cohen, who once served as a personal attorney to former President Donald Trump, turned over his cell phones to Manhattan prosecutors this week, CNN reports.This comes as the district attorney’s office investigates the Trump Organization’s role in the “hush money” that was given to former adult film actor Stormy Daniels during Trump’s 2016 presidential campaign. Cohen told CNN host Don Lemon, “Most recently, they asked for my cell phones because they want to be able to extract from it the voice recordings that I had had with Keith Davidson, former attorney to Stormy Daniels...

BrainStorm Cell Therapeutics GAAP EPS of -$0.34

Barclays PLC, a multinational financial services company headquartered in London, England, has recently purchased 9,219 shares of Establishment Labs Holdings Inc. (NASDAQ ESTA) for an undisclosed amount. The transaction was made through the company's investment arm, Barclays Global Investors.Establishment Labs Holdings Inc. is a biotechnology company that specializes in developing and commercializing novel therapies for rare genetic disorders. The company has a portfolio of clinical-stage programs targeting various diseases, including cystic fibrosis, sickle cell anemia, and inherited retinal diseases.Barclays PLC's investment in Establishment Labs Holdings Inc. is likely driven by the company's potential for growth and profitability. The biotechnology industry has seen significant growth in recent years, with many companies developing new therapies and treatments for rare genetic disorders. As a result, investors are increasingly interested in investing in this sector, as they seek to capitalize on the potential for high returns.It is worth noting that Barclays PLC's investment in Establishment Labs Holdings Inc. does not necessarily mean that the company will be acquired or merged with another organization. Rather, it may simply represent a strategic investment in a promising biotechnology company.

(marketscreener.com) Dima, Tristan, & Stephanie LIVING WITH SICKLE CELL DISEASE Corporate Effectiveness Addressing ESG & Long-term Sustainability April...https//www.marketscreener.com/quote/stock/EDITAS-MEDICINE-INC-26123639/news/Editas-Medicine-Corporate-Effectiveness-Report-April-2023-43496530/?utm_medium=RSS&utm_content=20230414

San Jose, California–(Newsfile Corp. – December 14, 2022) – Wearing custom cleats designed by Sickle Cell 101, scoring a game-changing touchdown, and winning the AFC Special Teams Player Of The Week, all while advocating for sickle cell—that’s Cleveland Browns’ wide receiver Donovan Peoples-Jones courageously supporting sickle cell for the third year in a row through […]

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https//www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

(marketscreener.com) Company Receives First Major Purchase Order in Saudi ArabiaTORRANCE, Calif., Nov. 17, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. , a leader in sickle cell disease treatment, announced today that it has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar...https//www.marketscreener.com/quote/stock/EMMAUS-LIFE-SCIENCES-INC-120797573/news/Emmaus-Life-Sciences-Receives-Endari-Marketing-Authorization-from-the-Qatar-Ministry-of-Public-Heal-42345524/?utm_medium=RSS&utm_content=20221117

Blood donations are now needed every day to treat people with sickle cell disease.

Commentary Curing HIV and sickle cell disease with gene-based therapy falls short if vulnerable populations in Africa are excluded.

Research reveals a promising stem cell approach to correct photoreceptor cell degeneration, which underlies several forms of visual decline and blindness.

(marketscreener.com) European Commission approves Enjaymo® for treatment of hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission has granted marketing authorization...https//www.marketscreener.com/quote/stock/SANOFI-4698/news/Press-Release-European-Commission-approves-Enjaymo-sutimlimab-for-treatment-of-hemolytic-anemia-42347048/?utm_medium=RSS&utm_content=20221117

Some people who have long lived with the disease say they worry about living as a healthy person, while others worry about the obstacles to getting treatment.

Research reveals a promising stem cell approach to correct photoreceptor cell degeneration, which underlies several forms of visual decline and blindness.

An international team of researchers lays the foundation to examine how extracellular RNA and its carrier proteins found in bodily fluids function in a healthy as well as a diseased setting, potentially providing a means to accurately implement early detection and monitor disease processes.

(marketscreener.com) Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 , will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the...https//www.marketscreener.com/quote/stock/LINEAGE-CELL-THERAPEUTICS-65218223/news/RG6501-OpRegen-Phase-1-2a-Clinical-Results-to-Be-Presented-at-2023-Retinal-Cell-and-Gene-Therapy-43291452/?utm_medium=RSS&utm_content=20230320

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests. 

Treatments involve adding a new gene, or using CRISPR to edit one.

The demand for blood to treat sickle cell disease has risen by over two thirds in the last five years, a report suggests.